ID | 60522 |
フルテキストURL | |
著者 |
Fujiwara, Tomohiro
Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
ORCID
Kaken ID
Kaneuchi, Yoichi
Oncology Service, The Royal Orthopaedic Hospital NHS Foundation Trust
Stevenson, Jonathan
Oncology Service, The Royal Orthopaedic Hospital NHS Foundation Trust
Parry, Michael
Kurisunkal, Vineet
Oncology Service, The Royal Orthopaedic Hospital NHS Foundation Trust
Clark, Rhys
Oncology Service, The Royal Orthopaedic Hospital NHS Foundation Trust
Tsuda, Yusuke
Oncology Service, The Royal Orthopaedic Hospital NHS Foundation Trust
Laitinen, Minna
Oncology Service, The Royal Orthopaedic Hospital NHS Foundation Trust
Grimer, Robert
Oncology Service, The Royal Orthopaedic Hospital NHS Foundation Trust
Jeys, Lee
Oncology Service, The Royal Orthopaedic Hospital NHS Foundation Trust
|
抄録 | Objectives
Survival in patients with chondrosarcomas has not improved over 40 years. Although emerging evidence has documented the efficacy of navigation-assisted surgery, the prognostic significance in chondrosarcomas remains unknown. We aimed to assess the clinical benefit of navigation-assisted surgery for pelvic chondrosarcomas involving the peri-acetabulum.
Methods
We studied 50 patients who underwent limb-sparing surgery for periacetabular chondrosarcomas performed with navigation (n = 13) without it (n = 37) at a referral musculoskeletal oncology centre between 2000 and 2015.
Results
The intralesional resection rates in the navigated and non-navigated groups were 8% (n = 1) and 19% (n = 7), respectively; all bone resection margins were clear in the navigated group. The 5-year cumulative incidence of local recurrence was 23% and 56% in the navigated and non-navigated groups, respectively (p = 0.035). There were no intra-operative complications related to use of navigation. There was a trend toward better functional outcomes in the navigated group (mean MSTS score, 67%) than the non-navigated group (mean MSTS score, 60%; p = 0.412). At a mean follow-up of 63 months, the 5-year disease-specific survival was 76% and 53% in the navigated and non-navigated group, respectively (p = 0.085), whilst the 5-year progression-free survival was 62% and 28% in the navigated and non-navigated group, respectively (p = 0.032).
Conclusion
This study confirmed improved local control and progression-free survival with the use of computer navigation in patients with limb-salvage surgery for periacetabular chondrosarcomas, although the advancement in other treatment modalities is required for improvement of disease-specific survival.
|
キーワード | Chondrosarcoma
Pelvis
Surgery
Navigation
|
備考 | This fulltext is available in Jul. 2021.
|
発行日 | 2020-07-03
|
出版物タイトル |
EJSO - European Journal of Surgical Oncology
|
巻 | 47巻
|
号 | 2号
|
出版者 | European Society of Surgical Oncology
|
開始ページ | 416
|
終了ページ | 423
|
ISSN | 0748-7983
|
NCID | AA10516435
|
資料タイプ |
学術雑誌論文
|
言語 |
英語
|
OAI-PMH Set |
岡山大学
|
論文のバージョン | author
|
PubMed ID | |
DOI | |
関連URL | isVersionOf https://doi.org/10.1016/j.ejso.2020.05.025
|